Skip to main content

Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery


via The Scientist RSS https://ift.tt/kIr9oEy Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. Using this assay, the cells were shown to be suitable for measuring cardiotoxicity, offering scientists a robust cardiac model for drug discovery and screening. https://ift.tt/fOjB64I August 02, 2022 at 10:54PM
Labels:

Comments

Post a Comment

Popular posts from this blog

Enhancing Cell Morphology-Based Analysis

via The Scientist RSS https://ift.tt/RkiFxGZ Learn how the latest AI-driven technology uses morphology to comprehensively analyze and sort cell populations. https://ift.tt/0hfk7tr August 03, 2023 at 10:19PM
Post a Comment
Read more

Accessible Lateral Flow Assays: Test to Treat, Test to Protect

via The Scientist RSS https://ift.tt/7aXpZQb From development to implementation, Rosanna Peeling discusses the importance of rapid tests for public health. https://ift.tt/xEQe8l9 October 18, 2023 at 08:30PM
Post a Comment
Read more

Engineered Bacteria Make Tumors More T Cell-Friendly

via The Scientist RSS https://ift.tt/Ku7FXvh Microbes designed to produce specific immunomodulatory metabolites could give immunotherapy a boost. https://ift.tt/xy2vXPZ April 08, 2022 at 08:41PM
Post a Comment
Read more